Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.
- Published in:
- Clinical Research in Cardiology Supplements, 2019, v. 14, p. 45, doi. 10.1007/s11789-019-00099-z
- By:
- Publication type:
- Article
Works matching IS 18610706 AND DT 2019 AND VI 14
Results: 9
1
2
Lipoprotein(a)—an interdisciplinary challenge.
- Published in:
- Clinical Research in Cardiology Supplements, 2019, v. 14, p. 20, doi. 10.1007/s11789-019-00098-0
- By:
- Publication type:
- Article
3
Lipoprotein(a) apheresis in patients with peripheral arterial disease: rationale and clinical results.
- Published in:
- Clinical Research in Cardiology Supplements, 2019, v. 14, p. 39, doi. 10.1007/s11789-019-00097-1
- By:
- Publication type:
- Article
4
Lipoprotein(a)—antisense therapy.
- Published in:
- Clinical Research in Cardiology Supplements, 2019, v. 14, p. 51, doi. 10.1007/s11789-019-00096-2
- By:
- Publication type:
- Article
5
Lipoprotein(a) and mortality—a high risk relationship.
- Published in:
- Clinical Research in Cardiology Supplements, 2019, v. 14, p. 13, doi. 10.1007/s11789-019-00095-3
- By:
- Publication type:
- Article
6
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
- Published in:
- Clinical Research in Cardiology Supplements, 2019, v. 14, p. 33, doi. 10.1007/s11789-019-00094-4
- By:
- Publication type:
- Article
7
Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region.
- Published in:
- Clinical Research in Cardiology Supplements, 2019, v. 14, p. 5, doi. 10.1007/s11789-019-00093-5
- By:
- Publication type:
- Article
8
Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism?
- Published in:
- Clinical Research in Cardiology Supplements, 2019, v. 14, p. 28, doi. 10.1007/s11789-019-00101-8
- By:
- Publication type:
- Article
9
Lipoprotein(a).
- Published in:
- 2019
- By:
- Publication type:
- Editorial